ImmunityBio Statistics
Total Valuation
ImmunityBio has a market cap or net worth of $8.54 billion. The enterprise value is $9.15 billion.
Important Dates
The last earnings date was Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmunityBio has 1.05 billion shares outstanding. The number of shares has increased by 29.76% in one year.
| Current Share Class | 1.05B |
| Shares Outstanding | 1.05B |
| Shares Change (YoY) | +29.76% |
| Shares Change (QoQ) | +3.76% |
| Owned by Insiders (%) | 28.24% |
| Owned by Institutions (%) | 16.32% |
| Float | 394.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 59.66 |
| Forward PS | 36.30 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 64.93 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.67
| Current Ratio | 6.67 |
| Quick Ratio | 6.24 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.33 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -34.38% |
| Return on Invested Capital (ROIC) | -67.01% |
| Return on Capital Employed (ROCE) | -45.17% |
| Weighted Average Cost of Capital (WACC) | 5.03% |
| Revenue Per Employee | $204,019 |
| Profits Per Employee | -$1.24M |
| Employee Count | 691 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 0.21 |
Taxes
In the past 12 months, ImmunityBio has paid $108,000 in taxes.
| Income Tax | 108,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +216.93% in the last 52 weeks. The beta is 0.07, so ImmunityBio's price volatility has been lower than the market average.
| Beta (5Y) | 0.07 |
| 52-Week Price Change | +216.93% |
| 50-Day Moving Average | 7.80 |
| 200-Day Moving Average | 4.54 |
| Relative Strength Index (RSI) | 52.27 |
| Average Volume (20 Days) | 12,256,530 |
Short Selling Information
The latest short interest is 140.33 million, so 13.40% of the outstanding shares have been sold short.
| Short Interest | 140.33M |
| Short Previous Month | 135.54M |
| Short % of Shares Out | 13.40% |
| Short % of Float | 35.61% |
| Short Ratio (days to cover) | 6.18 |
Income Statement
In the last 12 months, ImmunityBio had revenue of $140.98 million and -$854.53 million in losses. Loss per share was -$0.89.
| Revenue | 140.98M |
| Gross Profit | 140.04M |
| Operating Income | -261.39M |
| Pretax Income | -854.50M |
| Net Income | -854.53M |
| EBITDA | -245.41M |
| EBIT | -261.39M |
| Loss Per Share | -$0.89 |
Full Income StatementBalance Sheet
The company has $380.88 million in cash and $1.12 billion in debt, with a net cash position of -$743.73 million or -$0.71 per share.
| Cash & Cash Equivalents | 380.88M |
| Total Debt | 1.12B |
| Net Cash | -743.73M |
| Net Cash Per Share | -$0.71 |
| Equity (Book Value) | -869.13M |
| Book Value Per Share | -0.83 |
| Working Capital | 385.00M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$294.39 million and capital expenditures -$4.50 million, giving a free cash flow of -$298.89 million.
| Operating Cash Flow | -294.39M |
| Capital Expenditures | -4.50M |
| Depreciation & Amortization | 15.98M |
| Net Borrowing | 75.90M |
| Free Cash Flow | -298.89M |
| FCF Per Share | -$0.29 |
Full Cash Flow StatementMargins
| Gross Margin | 99.34% |
| Operating Margin | -185.41% |
| Pretax Margin | -606.12% |
| Profit Margin | n/a |
| EBITDA Margin | -174.08% |
| EBIT Margin | -185.41% |
| FCF Margin | n/a |
Dividends & Yields
ImmunityBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.76% |
| Shareholder Yield | -29.76% |
| Earnings Yield | -10.16% |
| FCF Yield | -3.55% |
Analyst Forecast
The average price target for ImmunityBio is $12.57, which is 54.23% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.57 |
| Price Target Difference | 54.23% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 76.31% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ImmunityBio has an Altman Z-Score of -8.48 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.48 |
| Piotroski F-Score | 3 |
